Business Wire

QPS Launches New Leukopak and Cell Therapy Products Facility

Share

QPS Holdings, LLC announced today that their Springfield campus, QPS Missouri, has launched a new Cell Therapy business unit. The unit’s first achievement is the opening of a new Leukopak collection and blood product processing center. This facility is designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. QPS is a full service CRO that’s dedicated to supporting drug development from conceptualization through to commercial launch. This facility is providing critical raw materials for the research and development of cell therapies but will soon be supporting clinical and commercial cell therapy companies and patients. In addition, this new facility will support the local economy by providing stipends to blood product donors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113328476/en/

The new QPS Cell Therapy Unit in Springfield, Missouri is a Leukopak collection and blood product processing center designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. (Photo: Business Wire)

To build out the facility and ensure the success of this new venture, QPS has hired Tia Hexom, PhD, (Senior Director of Cell Therapy Services and Manufacturing). With over a decade of experience in the cell therapy field, Hexom is excited to be building cell therapy capabilities in the Midwestern United States.

QPS Missouri is a division of QPS Holdings LLC, a global Clinical Research Organization (CRO) that conducts studies on behalf of pharmaceutical and biotech companies for the development of new and existing pharmaceutical products. This new Leukopak and Cell Therapy products donation and processing center will be housed in the same building as the new, state-of-the-art Screening and Recruitment Center that opened in July 2022, located at 2025 W. Sunshine Street, Springfield, MO. Study participants and blood product donors are paid a stipend for their participation in these Clinical Research activities. These stipends benefit the study participants and donors and, therefore, the local economy.

“Our participants and donors are a key part of the success of QPS in Springfield, Missouri and they continue to make a difference by helping advance drug development research,” states Brendon Bourg, Vice President, Early Phase Clinical/Head of Administration QPS Missouri. “To have the opportunity and ability to provide this type of supplemental income to our local community, while providing a valuable service to our pharmaceutical and biotech clients is something we (QPS) are honored to be a part of.”

Located in Springfield, QPS Missouri has been conducting clinical research studies for over 30 years, with the help of more than 50,000 study participants. In addition to the new Cell Therapy facilities, the Springfield campus houses five independent clinics with more than 240 beds, a pharmacy with a retention area, local and central CAP/CLIA safety lab, a clinical trial kit processing area, and a 2,500 square foot negative pressure room.

QPS has always been on the front line of clinical research in all areas of pharmaceutical and biotech drug development. Since opening its doors in Springfield in 1994, QPS Missouri has conducted more than 2,000 Phase I FDA-regulated studies and paid over $50 million to local participants and donors.

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, cell therapy products (such as Leukopaks and PBMCs), clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I clinical facilities, and multi-site clinical research services. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance, and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241113328476/en/

Contacts

Gabrielle Pastore, QPS Marketing
Phone: 302-287-7821
Email: gabrielle.pastore@qps.com
Website: www.qps.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.qps.com&esh
eet=54151703&newsitemid=20241113328476&lan=en-US&anchor=www.qps.com&index=2&md5=
8586b94df60fd6abd834882cd1e26b64

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Xsolla Expands Payment Coverage in Portugal With MB Way, a Leading Mobile Wallet Trusted by 6 Million Customers, to Unlock New Growth Opportunities for Game Developers20.1.2026 16:41:00 CET | Press Release

Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced the expansion of its payments solution in Portugal with the addition of MB Way. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120938007/en/ Graphic: Xsolla Portugal is a leader in digital transformation, with nearly 90% of its population online, high smartphone usage, and a strong adoption of mobile banking. Trusted by 6 million people, connected to 11 million cards, supported by 28 banks, and driving 496 million transactions in 2024, MB Way provides 95% market coverage, allowing most bank customers to use the service. MB Way is the leading mobile wallet in Portugal, with an estimated market share of 34%-45% of all e-commerce transactions locally. By adding MB Way as a payment method to its portfolio, Xsolla continues to deliver the fast and flexible payment experience Portuguese players expect. Key

Andersen Consulting Adds Collaborating Firm Africa International Advisors20.1.2026 15:30:00 CET | Press Release

Andersen Consulting extends its strategy and business transformation capabilities in Africa through a Collaboration Agreement with Africa International Advisors (AIA), a Johannesburg-based firm focusing on enhancing business competitiveness through sector specific insights, innovation and advisory services. Founded in 2002, AIA is a pan-African management consulting firm that delivers strategy-led advisory services with a focus on digital transformation and AI-driven business outcomes. The firm advises clients across sectors including energy and resources, oil and gas, infrastructure, trade and logistics, financial services, banking, and telecom. AIA’s strategic perspective, local credibility, and market access enable it to design and implement solutions that align people, processes, and technology to drive meaningful change. “From the beginning, our mission has been to drive progress through an Africa-centered lens, grounded in the realities and ambitions of the continent,” said Hasna

Balena Secures Strategic Growth Investment to Accelerate Edge AI and IoT Fleet Management20.1.2026 15:14:00 CET | Press Release

Balena, the leading platform for deploying, managing, and scaling fleets of edge computing and AI devices, today announced a strategic growth investment from LoneTree Capital (“LoneTree”), a New York-based growth capital firm. The partnership will accelerate Balena’s product innovation with a focus on Edge AI workloads and security features to meet evolving compliance needs, while expanding resources for customer success and global fleet support. Founded in 2011, Balena enables customers to leverage the ever-increasing power of technology to solve real-world problems by providing software to manage the full lifecycle of edge computing devices. The platform abstracts away infrastructure complexity, handling critical tasks like secure Over-The-Air (OTA) updates so engineering teams can focus on their core product. As a truly hardware-agnostic solution, Balena empowers customers to deploy their applications, including intensive Edge AI workloads, on the devices of their choice, avoiding v

SIRBAI Launches Middle East’s First AI-Powered Autonomous Drone Swarm Technology at UMEX 202620.1.2026 15:11:00 CET | Press Release

SIRBAI today announced the official launch of the Middle East’s first AI-powered autonomous drone swarm technology at UMEX 2026 - a global exhibition platform for unmanned systems and autonomous capabilities - marking the company’s entry into the defense technology sector. Designed for unmanned aerial systems (UAS), the platform enables multiple drones to operate collaboratively with a high degree of autonomy, even in complex and contested environments. As the first company in the region to offer this advanced capability, SIRBAI is set to redefine the modern battlefield with innovative and scalable autonomous technology, establishing new standards for resilient and operator-friendly mission systems for modern defense operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120186459/en/ SIRBAI Launches Middle East’s First AI-Powered Autonomous Drone Swarm Technology at UMEX 2026 (Photo: AETOSWire) SIRBAI enters the mark

FlightSafety International Receives EASA and UK CAA Certification for Gulfstream G700 Flight Simulator at Farnborough Learning Centre20.1.2026 15:05:00 CET | Press Release

FlightSafety International Inc. (FSI), a global leader in aviation training and simulation technology, announced today it has received European Union Aviation Safety Agency (EASA) and UK Civil Aviation Authority (CAA) certification for its Gulfstream G700 Full Flight Simulator (FFS), located at the company’s Farnborough Learning Centre. The certification of the simulator, which was engineered and manufactured by FSI, validates the advanced technology, accuracy, and fidelity of the flight training device, confirming it meets the highest European and UK regulatory standards. The FFS will be leveraged for initial, recurrent, and advanced pilot training to support G700 and Gulfstream G800 aircraft, further expanding global access to high-fidelity training. “The G700 simulator certification in Farnborough reinforces FSI’s long-standing commitment to supporting Gulfstream operators across Europe,” said David Mann, Farnborough Centre Manager, FlightSafety International. “It expands access to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye